Shots:

• The companies sign an agreement with the EC to supply 200M doses of BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2 to EU member states- with an option to request an additional 100M doses
• Deliveries are anticipated to start by the end of 2020- following clinical success and regulatory authorization. The companies expect to produce ~1.3B doses in 2021 globally
• Pfizer and BioNTech initiated a rolling submission to the EMA in Oct’2020 and will continue a regular and open dialogue with the EMA providing results from their ongoing P-III study

­  Ref: Pfizer | Image: MedPage Today